These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 8676351)
1. Antagonistic properties of centrally truncated analogs of [D-Trp(32)]NPY. Balasubramaniam A; Ujhelyi M; Borchers M; Huang Y; Zhai W; Zhou Y; Johnson M; Sheriff S; Fischer JE J Med Chem; 1996 Mar; 39(5):1142-7. PubMed ID: 8676351 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, structure, and antagonistic properties of des-Asn29[D-Trp28,32]NPY(27-36). Balasubramaniam A; Zhai W; Tao Z; Huang Y; Fischer JE; Eden P; Taylor JE; Kar L; Samarasinghe SD; Johnson ME Peptides; 1996; 17(7):1113-8. PubMed ID: 8959744 [TBL] [Abstract][Full Text] [Related]
3. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy. Michel MC; Gaida W; Beck-Sickinger AG; Wieland HA; Doods H; Dürr H; Jung G; Schnorrenberg G Mol Pharmacol; 1992 Oct; 42(4):642-8. PubMed ID: 1331755 [TBL] [Abstract][Full Text] [Related]
4. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226. Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543 [TBL] [Abstract][Full Text] [Related]
5. Conformational and biological studies of neuropeptide Y analogs containing structural alterations. Fournier A; Gagnon D; Quirion R; Cadieux A; Dumont Y; Pheng LH; St-Pierre S Mol Pharmacol; 1994 Jan; 45(1):93-101. PubMed ID: 8302286 [TBL] [Abstract][Full Text] [Related]
6. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mullins D; Kirby D; Hwa J; Guzzi M; Rivier J; Parker E Mol Pharmacol; 2001 Sep; 60(3):534-40. PubMed ID: 11502885 [TBL] [Abstract][Full Text] [Related]
7. Identification of high-potency neuropeptide Y analogues through systematic lactamization. Kirby DA; Britton KT; Aubert ML; Rivier JE J Med Chem; 1997 Jan; 40(2):210-5. PubMed ID: 9003519 [TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship of novel pentapeptide neuropeptide Y receptor antagonists is consistent with a noncontinuous epitope for ligand-receptor binding. Daniels AJ; Matthews JE; Viveros OH; Leban JJ; Cory M; Heyer D Mol Pharmacol; 1995 Sep; 48(3):425-32. PubMed ID: 7565622 [TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. Cabrele C; Beck-Sickinger AG J Pept Sci; 2000 Mar; 6(3):97-122. PubMed ID: 10759209 [TBL] [Abstract][Full Text] [Related]
10. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Kanatani A; Kanno T; Ishihara A; Hata M; Sakuraba A; Tanaka T; Tsuchiya Y; Mase T; Fukuroda T; Fukami T; Ihara M Biochem Biophys Res Commun; 1999 Dec; 266(1):88-91. PubMed ID: 10581170 [TBL] [Abstract][Full Text] [Related]
11. Endothelin (ET)-1-induced inhibition of ATP release from PC-12 cells is mediated by the ETB receptor: differential response to ET-1 on ATP, neuropeptide Y, and dopamine levels. Gardner A; Westfall TC; Macarthur H J Pharmacol Exp Ther; 2005 Jun; 313(3):1109-17. PubMed ID: 15687374 [TBL] [Abstract][Full Text] [Related]